Global Drugs of Abuse (DOA) Testing Market Key Players Competitive Survey Report 2023
Global Drugs of Abuse (DOA) Testing Market Key Players Competitive Survey Report 2023
Discover the latest insights into the booming Drugs of Abuse (DOA) Testing Market. This report analyzes market size, growth trends (CAGR ), key players, and regional performance, offering valuable data for investors and industry professionals. Explore market drivers, restraints, and future projections for -.
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
The global Drugs of Abuse (DOA) Testing market size in 2022 is 6253.3 million US dollars, and it is expected to be XX million US dollars by 2029, with a compound annual growth rate of 10.25% expected in 2023-2029.
MARKET COMPETITIVE LANDSCAPE:
The main players in the Drugs of Abuse (DOA) Testing market include Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Medtronic (Ireland), and Abbott (U.S.). The share of the top 3 players in the Drugs of Abuse (DOA) Testing market is XX%.
REGION SHARE:
The report covers the market size information of North America, Europe, Asia Pacific, Latin America, Middle East and Africa, and North America accounted for XX%, Europe accounted for XX% of Drugs of Abuse (DOA) Testing market, and Asia Pacific accounted for XX%.
SEGMENT OVERVIEW:
The report segments the market by Type and Application. Urine accounted for XX% of Drugs of Abuse (DOA) Testing market in 2022. Saliva share of XX%.
Pain Management accounted for XX% of the Drugs of Abuse (DOA) Testing market in 2022. Criminal Justice accounts for XX%.
Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
COVID-19 Impact:
Outbreak of COVID-19 pandemic due to lockdown restrictions imposed by governments around the world has affected the growth of the global Drugs of Abuse (DOA) Testing market in 2020. The containment measures taken by the governments of various countries in response to control the outbreak of COVID-19 disrupted the entire supply chain by creating logistical interruptions, transportation restrictions, and product supply across borders.
The report analyzes the key trends in each segment of the global Drugs of Abuse (DOA) Testing market along with global and country-level forecasts from 2023 to 2028. Our report segments the market based on types and applications, thereby providing a detailed analysis of the market to help gain an in-depth understanding of the market and enable market participants, stakeholders, investors, etc. to have a clearer understanding of the market and judgment.
Key benefits to stakeholders:
The report provides a comprehensive quantitative analysis of various segments, historical and current market trends, market forecasts, and dynamics of the Drugs of Abuse (DOA) Testing market for 2017-2028.
The research report provides the latest information on the market drivers, challenges and opportunities of the global Drugs of Abuse (DOA) Testing market.
The study profiles the leading as well as the fastest growing regional markets. It further enables stakeholders to identify key country-level markets within each region.
Porter's Five Forces Analysis helps stakeholders assess the impact of new entrants, competitors, supplier strength, buyer strength, and threat of substitution. It helps stakeholders analyze the level of competition in the Drugs of Abuse (DOA) Testing industry and its attractiveness.
The competitive landscape enables stakeholders to understand their competitive environment and gain insight into the current position of the key players in the market.
The life sciences industry grows and continues to advance, driving innovation and improving healthcare outcomes for individuals around the world.
Artificial Intelligence (AI) and Machine Learning (ML): AI and ML technologies are increasingly being employed in life sciences research and development. They aid in drug discovery, optimizing clinical trials, analyzing vast amounts of biological data, and identifying patterns that can lead to breakthroughs in understanding diseases and developing new therapies.
Digital Health Technologies: Digital health technologies have seen rapid growth, especially in areas like telemedicine, wearable devices, and mobile health applications. These technologies enable remote patient monitoring, facilitate better healthcare access, and empower individuals to manage their health more effectively.
Wearable Devices and Remote Monitoring: Wearable devices, such as smartwatches and fitness trackers, have become more sophisticated, enabling continuous monitoring of vital signs and health parameters. These devices offer opportunities for early detection of health issues and improved management of chronic conditions.
Market Data Breakdown by Regions
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Spain
Nordic
Asia Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
Egypt
South Africa
UAE
Turkey
Saudi Arabia
Some prominent players in the market includes:
Takeda Pharmaceutical Company Limited (Japan)
F. Hoffmann-La Roche Ltd (Switzerland)
Abbott (U.S.)
Medtronic (Ireland)
Abbott (U.S.)
BD (U.S.)
Johnson & Johnson Services, Inc. (U.S.)
GSK Plc. (U.K.)
Bayer AG (Germany)
Zimmer Biomet (U.S.)
Stryker Corporation (U.S.)
Homology Medicines, Inc (U.S.)
Novartis AG (Switzerland)
Pfizer Inc. (U.S.)
JCR Pharmaceuticals Co., Ltd. (Japan)
Sangamo Therapeutics (U.S.)
AVROBIO, Inc (U.S.)
REGENXBIO Inc (U.S)
CANbridge Life Sciences Ltd. (Taiwan)
Denali Therapeutics (U.S.)
Jasper Therapeutics, Inc. (U.S.)
Market Data Breakdown by Type
Urine
Saliva
Hair
Others
Market Data Breakdown by Applications
Pain Management
Criminal Justice
Workplace Screening
Table of Content
1 Drugs of Abuse (DOA) Testing Market Introduction and Overview
1.1 Drugs of Abuse (DOA) Testing Definition
1.2 Research Purposes
1.3 Report Timeline
1.4 Economic Analysis of Global Regions
1.5 Inflation Analysis
1.6 The Impact of the Russian-Ukrainian War on the Market
1.7 Coronavirus Disease 2020 (COVID-19) Impact on Global
2 Global Drugs of Abuse (DOA) Testing Historical Market Analysis by Type
2.1 Market Size Analysis by Types
2.2 Global Drugs of Abuse (DOA) Testing Revenue and Market Share by Type
3 Global Drugs of Abuse (DOA) Testing Historical Market Analysis by Application
3.1 Market Size Analysis by Application
3.2 Global Drugs of Abuse (DOA) Testing Revenue Market Share by Application (2018-2023)
4 Global Market Growth Trends Analysis
4.1 Global Drugs of Abuse (DOA) Testing Market Size (2018-2023)
4.2 Drugs of Abuse (DOA) Testing Growth Trends Analysis by Regions
4.2.1 Drugs of Abuse (DOA) Testing Market Size by Regions: 2018 VS 2023 VS 2029
4.2.2 Drugs of Abuse (DOA) Testing Historic Revenue Market Size by Regions (2018-2023)
4.2.3 North America Drugs of Abuse (DOA) Testing Market Size (2018-2023)
4.2.4 Europe Drugs of Abuse (DOA) Testing Market Size (2018-2023)
4.2.5 Asia-Pacific Drugs of Abuse (DOA) Testing Market Size (2018-2023)
4.2.6 Latin America Drugs of Abuse (DOA) Testing Market Size (2018-2023)
4.2.7 Middle East & Africa Drugs of Abuse (DOA) Testing Market Size (2018-2023)
5 North America
5.1 North America Drugs of Abuse (DOA) Testing Revenue by Countries
5.1.1 North America Drugs of Abuse (DOA) Testing Revenue by Countries (2018-2023)
5.2 North America Drugs of Abuse (DOA) Testing Revenue by Types
5.3 North America Drugs of Abuse (DOA) Testing Revenue by Applications
5.4 United States
5.5 Canada
6 Asia Pacific
6.1 Asia Pacific Drugs of Abuse (DOA) Testing Revenue by Countries
6.1.1 Asia Pacific Drugs of Abuse (DOA) Testing Revenue by Countries (2018-2023)
6.2 Asia Pacific Drugs of Abuse (DOA) Testing Revenue by Types
6.3 Asia Pacific Drugs of Abuse (DOA) Testing Revenue by Applications
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Drugs of Abuse (DOA) Testing Revenue by Countries
7.1.1 Europe Drugs of Abuse (DOA) Testing Revenue by Countries (2018-2023)
7.2 Europe Drugs of Abuse (DOA) Testing Revenue by Types
7.3 Europe Drugs of Abuse (DOA) Testing Revenue by Applications
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Nordic
8 Latin America
8.1 Latin America Drugs of Abuse (DOA) Testing Revenue by Countries
8.1.1 Latin America Drugs of Abuse (DOA) Testing Revenue by Countries (2018-2023)
8.2 Latin America Drugs of Abuse (DOA) Testing Revenue by Types
8.3 Latin America Drugs of Abuse (DOA) Testing Revenue by Applications
8.4 Brazil
8.5 Argentina
8.6 Mexico
9 Middle East & Africa
9.1 Middle East & Africa Drugs of Abuse (DOA) Testing Revenue by Countries
9.1.1 Middle East & Africa Drugs of Abuse (DOA) Testing Revenue by Countries (2018-2023)
9.2 Middle East & Africa Drugs of Abuse (DOA) Testing Revenue by Types
9.3 Middle East & Africa Drugs of Abuse (DOA) Testing Revenue by Applications
9.4 Egypt
9.5 South Africa
9.6 UAE
9.7 Turkey
9.8 Saudi Arabia
10 Global Drugs of Abuse (DOA) Testing Market Competition, by Players
10.1 Global Drugs of Abuse (DOA) Testing Revenue and Market Share by Players
10.2 Market Concentration Rate
10.2.1 Top 3 Drugs of Abuse (DOA) Testing Players Market Share in 2022
10.2.2 Top 6 Drugs of Abuse (DOA) Testing Players Market Share in 2022
10.2.3 Market Competition Trend
10.3 Drugs of Abuse (DOA) Testing Players Head Office, Business Provided
10.4 Drugs of Abuse (DOA) Testing Mergers & Acquisitions
10.5 Drugs of Abuse (DOA) Testing New Entrants and Expansion Plans
11 Players Profiles11.1 Takeda Pharmaceutical Company Limited (Japan)
11.1.1 Takeda Pharmaceutical Company Limited (Japan) Company Profile
11.1.2 Drugs of Abuse (DOA) Testing Product Overview
11.1.3 Takeda Pharmaceutical Company Limited (Japan) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.1.4 Takeda Pharmaceutical Company Limited (Japan) Business Overview
11.1.5 Recent Developments and Plans
11.2 F. Hoffmann-La Roche Ltd (Switzerland)
11.2.1 F. Hoffmann-La Roche Ltd (Switzerland) Company Profile
11.2.2 Drugs of Abuse (DOA) Testing Product Overview
11.2.3 F. Hoffmann-La Roche Ltd (Switzerland) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.2.4 F. Hoffmann-La Roche Ltd (Switzerland) Business Overview
11.2.5 Recent Developments and Plans
11.3 Abbott (U.S.)
11.3.1 Abbott (U.S.) Company Profile
11.3.2 Drugs of Abuse (DOA) Testing Product Overview
11.3.3 Abbott (U.S.) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.3.4 Abbott (U.S.) Business Overview
11.3.5 Recent Developments and Plans
11.4 Medtronic (Ireland)
11.4.1 Medtronic (Ireland) Company Profile
11.4.2 Drugs of Abuse (DOA) Testing Product Overview
11.4.3 Medtronic (Ireland) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.4.4 Medtronic (Ireland) Business Overview
11.4.5 Recent Developments and Plans
11.5 Abbott (U.S.)
11.5.1 Abbott (U.S.) Company Profile
11.5.2 Drugs of Abuse (DOA) Testing Product Overview
11.5.3 Abbott (U.S.) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.5.4 Abbott (U.S.) Business Overview
11.5.5 Recent Developments and Plans
11.6 BD (U.S.)
11.6.1 BD (U.S.) Company Profile
11.6.2 Drugs of Abuse (DOA) Testing Product Overview
11.6.3 BD (U.S.) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.6.4 BD (U.S.) Business Overview
11.6.5 Recent Developments and Plans
11.7 Johnson & Johnson Services, Inc. (U.S.)
11.7.1 Johnson & Johnson Services, Inc. (U.S.) Company Profile
11.7.2 Drugs of Abuse (DOA) Testing Product Overview
11.7.3 Johnson & Johnson Services, Inc. (U.S.) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.7.4 Johnson & Johnson Services, Inc. (U.S.) Business Overview
11.7.5 Recent Developments and Plans
11.8 GSK Plc. (U.K.)
11.8.1 GSK Plc. (U.K.) Company Profile
11.8.2 Drugs of Abuse (DOA) Testing Product Overview
11.8.3 GSK Plc. (U.K.) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.8.4 GSK Plc. (U.K.) Business Overview
11.8.5 Recent Developments and Plans
11.9 Bayer AG (Germany)
11.9.1 Bayer AG (Germany) Company Profile
11.9.2 Drugs of Abuse (DOA) Testing Product Overview
11.9.3 Bayer AG (Germany) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.9.4 Bayer AG (Germany) Business Overview
11.9.5 Recent Developments and Plans
11.10 Zimmer Biomet (U.S.)
11.10.1 Zimmer Biomet (U.S.) Company Profile
11.10.2 Drugs of Abuse (DOA) Testing Product Overview
11.10.3 Zimmer Biomet (U.S.) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.10.4 Zimmer Biomet (U.S.) Business Overview
11.10.5 Recent Developments and Plans
11.11 Stryker Corporation (U.S.)
11.11.1 Stryker Corporation (U.S.) Company Profile
11.11.2 Drugs of Abuse (DOA) Testing Product Overview
11.11.3 Stryker Corporation (U.S.) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.11.4 Stryker Corporation (U.S.) Business Overview
11.11.5 Recent Developments and Plans
11.12 Homology Medicines, Inc (U.S.)
11.12.1 Homology Medicines, Inc (U.S.) Company Profile
11.12.2 Drugs of Abuse (DOA) Testing Product Overview
11.12.3 Homology Medicines, Inc (U.S.) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.12.4 Homology Medicines, Inc (U.S.) Business Overview
11.12.5 Recent Developments and Plans
11.13 Novartis AG (Switzerland)
11.13.1 Novartis AG (Switzerland) Company Profile
11.13.2 Drugs of Abuse (DOA) Testing Product Overview
11.13.3 Novartis AG (Switzerland) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.13.4 Novartis AG (Switzerland) Business Overview
11.13.5 Recent Developments and Plans
11.14 Pfizer Inc. (U.S.)
11.14.1 Pfizer Inc. (U.S.) Company Profile
11.14.2 Drugs of Abuse (DOA) Testing Product Overview
11.14.3 Pfizer Inc. (U.S.) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.14.4 Pfizer Inc. (U.S.) Business Overview
11.14.5 Recent Developments and Plans
11.15 JCR Pharmaceuticals Co., Ltd. (Japan)
11.15.1 JCR Pharmaceuticals Co., Ltd. (Japan) Company Profile
11.15.2 Drugs of Abuse (DOA) Testing Product Overview
11.15.3 JCR Pharmaceuticals Co., Ltd. (Japan) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.15.4 JCR Pharmaceuticals Co., Ltd. (Japan) Business Overview
11.15.5 Recent Developments and Plans
11.16 Sangamo Therapeutics (U.S.)
11.16.1 Sangamo Therapeutics (U.S.) Company Profile
11.16.2 Drugs of Abuse (DOA) Testing Product Overview
11.16.3 Sangamo Therapeutics (U.S.) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.16.4 Sangamo Therapeutics (U.S.) Business Overview
11.16.5 Recent Developments and Plans
11.17 AVROBIO, Inc (U.S.)
11.17.1 AVROBIO, Inc (U.S.) Company Profile
11.17.2 Drugs of Abuse (DOA) Testing Product Overview
11.17.3 AVROBIO, Inc (U.S.) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.17.4 AVROBIO, Inc (U.S.) Business Overview
11.17.5 Recent Developments and Plans
11.18 REGENXBIO Inc (U.S)
11.18.1 REGENXBIO Inc (U.S) Company Profile
11.18.2 Drugs of Abuse (DOA) Testing Product Overview
11.18.3 REGENXBIO Inc (U.S) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.18.4 REGENXBIO Inc (U.S) Business Overview
11.18.5 Recent Developments and Plans
11.19 CANbridge Life Sciences Ltd. (Taiwan)
11.19.1 CANbridge Life Sciences Ltd. (Taiwan) Company Profile
11.19.2 Drugs of Abuse (DOA) Testing Product Overview
11.19.3 CANbridge Life Sciences Ltd. (Taiwan) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.19.4 CANbridge Life Sciences Ltd. (Taiwan) Business Overview
11.19.5 Recent Developments and Plans
11.20 Denali Therapeutics (U.S.)
11.20.1 Denali Therapeutics (U.S.) Company Profile
11.20.2 Drugs of Abuse (DOA) Testing Product Overview
11.20.3 Denali Therapeutics (U.S.) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.20.4 Denali Therapeutics (U.S.) Business Overview
11.20.5 Recent Developments and Plans
11.21 Jasper Therapeutics, Inc. (U.S.)
11.21.1 Jasper Therapeutics, Inc. (U.S.) Company Profile
11.21.2 Drugs of Abuse (DOA) Testing Product Overview
11.21.3 Jasper Therapeutics, Inc. (U.S.) Drugs of Abuse (DOA) Testing Market Performance (2018-2023)
11.21.4 Jasper Therapeutics, Inc. (U.S.) Business Overview
11.21.5 Recent Developments and Plans
12 Global Drugs of Abuse (DOA) Testing Forecast Market Analysis by Type
12.1 Global Drugs of Abuse (DOA) Testing Revenue Market Forecast by Type (2023-2029)
13 Global Drugs of Abuse (DOA) Testing Forecast Market Analysis by Application
13.1 Drugs of Abuse (DOA) Testing Revenue Market Forecast by Application (2023-2029)
14 Global Market Growth Forecast Analysis
14.1 Global Drugs of Abuse (DOA) Testing Forecast Market Size (2023-2029)
14.2 Drugs of Abuse (DOA) Testing Growth Trends Forecast Analysis by Regions
14.2.1 Drugs of Abuse (DOA) Testing Revenue Forecast Market Size by Regions (2023-2029)
14.2.2 North America Drugs of Abuse (DOA) Testing Forecast Market Size (2023-2029)
14.2.3 Europe Drugs of Abuse (DOA) Testing Forecast Market Size (2023-2029)
14.2.4 Asia-Pacific Drugs of Abuse (DOA) Testing Forecast Market Size (2023-2029)
14.2.5 Latin America Drugs of Abuse (DOA) Testing Forecast Market Size (2023-2029)
14.2.6 Middle East & Africa Drugs of Abuse (DOA) Testing Forecast Market Size (2023-2029)
15 Drugs of Abuse (DOA) Testing Industry Dynamic Analysis
15.1 Drugs of Abuse (DOA) Testing Market Trends Analysis
15.2 Drugs of Abuse (DOA) Testing Market Drivers Analysis
15.3 Drugs of Abuse (DOA) Testing Market Challenges Analysis
15.4 Drugs of Abuse (DOA) Testing Market Restraints Analysis
Tables & Figures:
List of Tables and Figures
Figure Drugs of Abuse (DOA) Testing Picture
Table Product Definition of Drugs of Abuse (DOA) Testing
Table Economic Analysis of Global Regions
Table Inflation Analysis
Table The Impact of the Russian-Ukrainian War on the Market
Figure 2020 (COVID-19) Impact on Global Economic Growth 2019, 2020, 2021
Figure Population infected by the Covid-19 of Major Countries
Table Global Drugs of Abuse (DOA) Testing Market Size by Type (2018 VS 2023 VS 2029)
Table Global Drugs of Abuse (DOA) Testing Revenue and Market Size by Type (2018-2023)
Table Global Drugs of Abuse (DOA) Testing Revenue and Market Share by Type (2018-2023)
Table Global Drugs of Abuse (DOA) Testing Market Size by Application (2018 VS 2023 VS 2029)
Table Global Drugs of Abuse (DOA) Testing Revenue Market Size by Application (2018-2023)
Table Global Drugs of Abuse (DOA) Testing Revenue Market Share by Application (2018-2023)
Figure Global Drugs of Abuse (DOA) Testing Revenue Market Size (2018-2023)
Table Drugs of Abuse (DOA) Testing Market Size by Regions: 2018 VS 2023 VS 2029
Table Drugs of Abuse (DOA) Testing Historic Revenue Market Size by Regions (2018-2023)
Table Drugs of Abuse (DOA) Testing Historic Revenue Market Share by Regions (2018-2023)
Figure North America Drugs of Abuse (DOA) Testing Market Size (2018-2023)
Figure Europe Drugs of Abuse (DOA) Testing Market Size (2018-2023)
Figure Asia-Pacific Drugs of Abuse (DOA) Testing Market Size (2018-2023)
Figure Latin America Drugs of Abuse (DOA) Testing Market Size (2018-2023)
Figure Middle East & Africa Drugs of Abuse (DOA) Testing Market Size (2018-2023)
Table North America Drugs of Abuse (DOA) Testing Revenue by Countries (2018-2023)
Table North America Drugs of Abuse (DOA) Testing Revenue Market Share by Countries (2018-2023)
Table North America Drugs of Abuse (DOA) Testing Revenue by Types (2018-2023)
Table North America Drugs of Abuse (DOA) Testing Revenue Market Share by Types (2018-2023)
Table North America Drugs of Abuse (DOA) Testing Revenue by Applications (2018-2023)
Table North America Drugs of Abuse (DOA) Testing Revenue Market Share by Applications (2018-2023)
Figure United States Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Figure Canada Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Table Asia-Pacific Drugs of Abuse (DOA) Testing Revenue by Countries (2018-2023)
Table Asia-Pacific Drugs of Abuse (DOA) Testing Revenue Market Share by Countries (2018-2023)
Table Asia Pacific Drugs of Abuse (DOA) Testing Revenue by Types (2018-2023)
Table Asia Pacific Drugs of Abuse (DOA) Testing Revenue Market Share by Types (2018-2023)
Table Asia Pacific Drugs of Abuse (DOA) Testing Revenue by Applications (2018-2023)
Table Asia Pacific Drugs of Abuse (DOA) Testing Revenue Market Share by Applications (2018-2023)
Figure China Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Figure Japan Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Figure Korea Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Figure Southeast Asia Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Figure India Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Figure Australia Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Table Europe Drugs of Abuse (DOA) Testing Revenue by Countries (2018-2023)
Table Europe Drugs of Abuse (DOA) Testing Revenue Market Share by Countries (2018-2023)
Table Europe Drugs of Abuse (DOA) Testing Revenue by Types (2018-2023)
Table Europe Drugs of Abuse (DOA) Testing Revenue Market Share by Types (2018-2023)
Table Europe Drugs of Abuse (DOA) Testing Revenue by Applications (2018-2023)
Table Europe Drugs of Abuse (DOA) Testing Revenue Market Share by Applications (2018-2023)
Figure Germany Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Figure France Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Figure UK Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Figure Italy Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Figure Russia Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Figure Spain Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Figure Nordic Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Table Latin America Drugs of Abuse (DOA) Testing Revenue by Countries (2018-2023)
Table Latin America Drugs of Abuse (DOA) Testing Revenue Market Share by Countries (2018-2023)
Table Latin America Drugs of Abuse (DOA) Testing Revenue by Types (2018-2023)
Table Latin America Drugs of Abuse (DOA) Testing Revenue Market Share by Types (2018-2023)
Table Latin America Drugs of Abuse (DOA) Testing Revenue by Applications (2018-2023)
Table Latin America Drugs of Abuse (DOA) Testing Revenue Market Share by Applications (2018-2023)
Figure Brazil Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Figure Argentina Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Figure Mexico Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Table Middle East & Africa Drugs of Abuse (DOA) Testing Revenue by Countries (2018-2023)
Table Middle East & Africa Drugs of Abuse (DOA) Testing Revenue Market Share by Countries (2018-2023)
Table Middle East & Africa Drugs of Abuse (DOA) Testing Revenue by Types (2018-2023)
Table Middle East & Africa Drugs of Abuse (DOA) Testing Revenue Market Share by Types (2018-2023)
Table Middle East & Africa Drugs of Abuse (DOA) Testing Revenue by Applications (2018-2023)
Table Middle East & Africa Drugs of Abuse (DOA) Testing Revenue Market Share by Applications (2018-2023)
Figure Egypt Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Figure South Africa Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Figure UAE Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Figure Turkey Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Figure Saudi Arabia Drugs of Abuse (DOA) Testing Revenue and Growth (2018-2023)
Table Global Drugs of Abuse (DOA) Testing Revenue by Players (2018-2023)
Table Global Drugs of Abuse (DOA) Testing Revenue Market Share by Players (2018-2023)
Figure Global Top 3 Companies Revenue Share in 2022
Figure Global Top 6 Companies Revenue Share in 2022
Table Global Drugs of Abuse (DOA) Testing Players Market Concentration Ratio (CR5) (2018-2023)
Table Drugs of Abuse (DOA) Testing Players Head Office, Business Provided
Table Mergers & Acquisitions
Table New Entrants and Expansion Plans
Table Takeda Pharmaceutical Company Limited (Japan) Profile
Table Product Overview
Table Takeda Pharmaceutical Company Limited (Japan) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure Takeda Pharmaceutical Company Limited (Japan) Revenue and Growth Rate
Figure Takeda Pharmaceutical Company Limited (Japan) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table F. Hoffmann-La Roche Ltd (Switzerland) Profile
Table Product Overview
Table F. Hoffmann-La Roche Ltd (Switzerland) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure F. Hoffmann-La Roche Ltd (Switzerland) Revenue and Growth Rate
Figure F. Hoffmann-La Roche Ltd (Switzerland) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Abbott (U.S.) Profile
Table Product Overview
Table Abbott (U.S.) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure Abbott (U.S.) Revenue and Growth Rate
Figure Abbott (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Medtronic (Ireland) Profile
Table Product Overview
Table Medtronic (Ireland) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure Medtronic (Ireland) Revenue and Growth Rate
Figure Medtronic (Ireland) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Abbott (U.S.) Profile
Table Product Overview
Table Abbott (U.S.) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure Abbott (U.S.) Revenue and Growth Rate
Figure Abbott (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table BD (U.S.) Profile
Table Product Overview
Table BD (U.S.) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure BD (U.S.) Revenue and Growth Rate
Figure BD (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Johnson & Johnson Services, Inc. (U.S.) Profile
Table Product Overview
Table Johnson & Johnson Services, Inc. (U.S.) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure Johnson & Johnson Services, Inc. (U.S.) Revenue and Growth Rate
Figure Johnson & Johnson Services, Inc. (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table GSK Plc. (U.K.) Profile
Table Product Overview
Table GSK Plc. (U.K.) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure GSK Plc. (U.K.) Revenue and Growth Rate
Figure GSK Plc. (U.K.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Bayer AG (Germany) Profile
Table Product Overview
Table Bayer AG (Germany) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure Bayer AG (Germany) Revenue and Growth Rate
Figure Bayer AG (Germany) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Zimmer Biomet (U.S.) Profile
Table Product Overview
Table Zimmer Biomet (U.S.) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure Zimmer Biomet (U.S.) Revenue and Growth Rate
Figure Zimmer Biomet (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Stryker Corporation (U.S.) Profile
Table Product Overview
Table Stryker Corporation (U.S.) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure Stryker Corporation (U.S.) Revenue and Growth Rate
Figure Stryker Corporation (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Homology Medicines, Inc (U.S.) Profile
Table Product Overview
Table Homology Medicines, Inc (U.S.) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure Homology Medicines, Inc (U.S.) Revenue and Growth Rate
Figure Homology Medicines, Inc (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Novartis AG (Switzerland) Profile
Table Product Overview
Table Novartis AG (Switzerland) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure Novartis AG (Switzerland) Revenue and Growth Rate
Figure Novartis AG (Switzerland) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Pfizer Inc. (U.S.) Profile
Table Product Overview
Table Pfizer Inc. (U.S.) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure Pfizer Inc. (U.S.) Revenue and Growth Rate
Figure Pfizer Inc. (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table JCR Pharmaceuticals Co., Ltd. (Japan) Profile
Table Product Overview
Table JCR Pharmaceuticals Co., Ltd. (Japan) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure JCR Pharmaceuticals Co., Ltd. (Japan) Revenue and Growth Rate
Figure JCR Pharmaceuticals Co., Ltd. (Japan) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Sangamo Therapeutics (U.S.) Profile
Table Product Overview
Table Sangamo Therapeutics (U.S.) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure Sangamo Therapeutics (U.S.) Revenue and Growth Rate
Figure Sangamo Therapeutics (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table AVROBIO, Inc (U.S.) Profile
Table Product Overview
Table AVROBIO, Inc (U.S.) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure AVROBIO, Inc (U.S.) Revenue and Growth Rate
Figure AVROBIO, Inc (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table REGENXBIO Inc (U.S) Profile
Table Product Overview
Table REGENXBIO Inc (U.S) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure REGENXBIO Inc (U.S) Revenue and Growth Rate
Figure REGENXBIO Inc (U.S) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table CANbridge Life Sciences Ltd. (Taiwan) Profile
Table Product Overview
Table CANbridge Life Sciences Ltd. (Taiwan) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure CANbridge Life Sciences Ltd. (Taiwan) Revenue and Growth Rate
Figure CANbridge Life Sciences Ltd. (Taiwan) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Denali Therapeutics (U.S.) Profile
Table Product Overview
Table Denali Therapeutics (U.S.) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure Denali Therapeutics (U.S.) Revenue and Growth Rate
Figure Denali Therapeutics (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Jasper Therapeutics, Inc. (U.S.) Profile
Table Product Overview
Table Jasper Therapeutics, Inc. (U.S.) Drugs of Abuse (DOA) Testing Revenue, Gross and Gross Margin (2018-2023)
Figure Jasper Therapeutics, Inc. (U.S.) Revenue and Growth Rate
Figure Jasper Therapeutics, Inc. (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Global Drugs of Abuse (DOA) Testing Revenue Market Size Forecast by Type (2023-2029)
Table Global Drugs of Abuse (DOA) Testing Revenue Market Share Forecast by Type (2023-2029)
Table Global Drugs of Abuse (DOA) Testing Revenue Market Size by Application (2023-2029)
Table Global Drugs of Abuse (DOA) Testing Revenue Market Share by Application (2023-2029)
Figure Global Drugs of Abuse (DOA) Testing Revenue Forecast Market Size (2023-2029)
Table Drugs of Abuse (DOA) Testing Revenue Forecast Market Size by Regions (2023-2029)
Table Drugs of Abuse (DOA) Testing Revenue Forecast Market Share by Regions (2023-2029)
Figure North America Drugs of Abuse (DOA) Testing Revenue Forecast Market Size (2023-2029)
Figure Europe Drugs of Abuse (DOA) Testing Revenue Forecast Market Size (2023-2029)
Figure Asia-Pacific Drugs of Abuse (DOA) Testing Revenue Forecast Market Size (2023-2029)
Figure Latin America Drugs of Abuse (DOA) Testing Revenue Forecast Market Size (2023-2029)
Figure Middle East & Africa Drugs of Abuse (DOA) Testing Revenue Forecast Market Size (2023-2029)
Table Market Trends Analysis
Table Market Drivers Analysis
Table Market Challenges Analysis
Table Market Restraints Analysis
Research Methodology:
Drugs of Abuse (DOA) Testing Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|